UK-based Futura Medical secures a key US patent allowance, safeguarding its erectile dysfunction gel Eroxon and an investigational women's sexual health treatment until 2040, while triggering a $2.5 million milestone payment from partner Haleon.
Biopharmaceutical firm Ardelyx has been granted a crucial U.S. patent covering the oral formulation of its drug tenapanor, solidifying protection for its commercial products Ibsrela and Xphozah until late 2042 and bolstering its competitive position in the chronic kidney disease treatment landscape.
In his inaugural strategic outlook, GSK's new CEO Luke Miels signaled a deliberate shift towards pipeline expansion to navigate the impending patent expiries of key HIV drugs, projecting a moderation in sales growth for 2026.
While Merck (MSD) delivered robust fourth-quarter results, its forecast for 2026 fell below Wall Street expectations, highlighting investor anxiety over impending patent expiries for blockbuster drugs like Keytruda.
Merck & Co. projected 2026 revenue below Wall Street expectations, citing a steeper-than-anticipated impact from patent expirations on key drugs like Januvia. The forecast overshadowed a strong Q4 performance driven by its blockbuster cancer therapy, Keytruda.
Credo Technology Group is deepening its integration into hyperscale AI infrastructure through the launch of its high-bandwidth Blue Heron retimer and a strategic patent licensing agreement with 3M, positioning itself as a key enabler for next-generation AI clusters.
InterDigital, Inc. (IDCC) has bolstered its licensing program with a renewed agreement with LG Electronics and issued its 2026 financial outlook, projecting revenue between $675 million and $775 million. The move underscores the firm's pivotal role in standard-essential patents for consumer electronics.
Despite a partial recovery, Pfizer's stock remains significantly below its pandemic-era peak. As 2026 approaches, the pharmaceutical giant confronts a critical juncture defined by looming patent expirations, a high-stakes catch-up effort in the lucrative GLP-1 market, and a dividend under pressure.
Meta Platforms confronts significant legal challenges on two fronts: a multi-billion dollar patent infringement lawsuit targeting its smart glasses technology and a high-stakes trial in New Mexico over child safety allegations. These proceedings could impact the company's hardware roadmap, policy decisions, and investor sentiment.
Fox Corporation surpassed Wall Street's revenue and profit forecasts for the fourth quarter of 2025, driven by resilient advertising demand for its core news and sports programming and accelerating growth from its digital streaming services, Tubi and Fox One.
Fox Corporation surpassed Wall Street's revenue forecasts for its fiscal second quarter, driven by robust advertising demand for Fox News and Major League Baseball playoffs, even without the boost of a major election cycle.
In a scathing critique, former executive editor Marty Baron lambasts owner Jeff Bezos's stewardship, linking strategic missteps to a wave of layoffs and diminished ambitions at the historic newspaper.
The Washington Post has initiated a major restructuring, resulting in hundreds of layoffs across its newsroom, including the closure of its storied sports desk. The move comes despite direct appeals from reporters to owner Jeff Bezos and signals a sharp strategic pivot.
USAA and Regions Bank have confidentially settled their mutual patent infringement lawsuits over remote check deposit technology, bringing a contentious legal battle in a favored patent court to a close. Terms were not disclosed.
In a rare public rebuke, former executive editor Marty Baron condemned the deep staff cuts and strategic shifts ordered by owner Jeff Bezos, calling the move a betrayal of the newspaper's journalistic mission.
Fox Corporation reported a 2% rise in Q2 revenue to $5.18 billion, fueled by robust advertising in news and sports, record engagement at Tubi, and the promising early performance of its new streaming service, Fox One. The media giant enters the second half of its fiscal year with confidence in its live-focused strategy.
The Washington Post has eliminated its standalone sports department and reduced headcount across nearly all news divisions, part of a sweeping restructuring aimed at achieving financial stability by 2026.
Pfizer reported a mixed fourth quarter, beating internal financial targets while navigating a post-COVID revenue decline. The pharmaceutical giant spotlighted strong growth from new products and a promising monthly obesity drug candidate, even as it braces for a wave of patent expirations and reaffirms its 2026 outlook.
News Corp is set to report quarterly earnings Thursday afternoon, with investors eyeing its digital transition and advertising resilience. Analysts project modest revenue growth as the media conglomerate navigates a shifting landscape.
Goldman Sachs maintains a Neutral stance on Pfizer (PFE) with a $26 price target, as the pharmaceutical giant navigates significant margin pressures from looming patent expiries and a constrained business development budget.
